DURECT Corp
DRRX1.910USD
0.000
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
59.29MCap. mercado
PérdidaP/E TTM
Más Datos de DURECT Corp Compañía
DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has also completed Alcohol-Associated Hepatitis (AHFIRM) Phase 2b study.
Información de la empresa
Símbolo de cotizaciónDRRX
Nombre de la empresaDURECT Corp
Fecha de salida a bolsaSep 28, 2000
Director ejecutivoMr. James E. Brown
Número de empleados21
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 28
Dirección10240 Bubb Road
CiudadCUPERTINO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal95014
Teléfono14087771417
Sitio Webhttps://www.durect.com/
Símbolo de cotizaciónDRRX
Fecha de salida a bolsaSep 28, 2000
Director ejecutivoMr. James E. Brown
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ashley Robinson
Mr. Ashley Robinson
Investor Relations Officer
Investor Relations Officer
--
--
Mr. Timothy M. Papp
Mr. Timothy M. Papp
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. James E. Brown
Mr. James E. Brown
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Norman L. Sussman, M.D.
Dr. Norman L. Sussman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ashley Robinson
Mr. Ashley Robinson
Investor Relations Officer
Investor Relations Officer
--
--
Mr. Timothy M. Papp
Mr. Timothy M. Papp
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. James E. Brown
Mr. James E. Brown
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Norman L. Sussman, M.D.
Dr. Norman L. Sussman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Europe
172.00K
53.58%
United States
117.00K
36.45%
Other
32.00K
9.97%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 14 de sep
Actualizado: dom., 14 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Asen (Scott R.)
10.31%
Richmond Brothers, Inc.
4.68%
Ingalls & Snyder LLC (Asset Management)
4.35%
The Vanguard Group, Inc.
4.08%
Dalton Investments, Inc.
2.40%
Otro
74.18%
Accionistas
Accionistas
Proporción
Asen (Scott R.)
10.31%
Richmond Brothers, Inc.
4.68%
Ingalls & Snyder LLC (Asset Management)
4.35%
The Vanguard Group, Inc.
4.08%
Dalton Investments, Inc.
2.40%
Otro
74.18%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
12.88%
Individual Investor
11.00%
Investment Advisor/Hedge Fund
9.79%
Hedge Fund
0.60%
Research Firm
0.27%
Venture Capital
0.04%
Otro
65.43%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
108
10.77M
34.70%
-3.79M
2025Q1
115
10.47M
33.77%
-4.69M
2024Q4
121
10.25M
33.03%
-6.31M
2024Q3
136
10.05M
32.37%
-5.85M
2024Q2
154
9.42M
30.55%
-4.23M
2024Q1
183
8.84M
28.67%
-5.03M
2023Q4
192
7.39M
25.17%
-5.35M
2023Q3
219
10.25M
37.42%
-1.75M
2023Q2
226
9.55M
39.01%
-2.60M
2023Q1
233
10.65M
43.65%
-399.75K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Asen (Scott R.)
3.08M
9.92%
+468.56K
+17.94%
Dec 31, 2024
Richmond Brothers, Inc.
1.35M
4.34%
+65.23K
+5.09%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
1.33M
4.3%
-256.06K
-16.10%
Mar 31, 2025
The Vanguard Group, Inc.
1.27M
4.08%
+128.60K
+11.29%
Mar 31, 2025
Dalton Investments, Inc.
512.31K
1.65%
+267.31K
+109.11%
Mar 31, 2025
Gagnon Securities LLC
403.88K
1.3%
+1.87K
+0.47%
Mar 31, 2025
Geode Capital Management, L.L.C.
333.33K
1.07%
+4.34K
+1.32%
Mar 31, 2025
Beirne Wealth Consulting Services, LLC
296.35K
0.95%
-29.52K
-9.06%
Mar 31, 2025
Montchanin Asset Management, LLC
310.12K
1%
+6.09K
+2.00%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
280.82K
0.9%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Fecha
Tipo
Relación
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
